Variable access to clopidogrel in a harmonized EU market

Value in Health

Volumn 11, Issue 5, 2008, Pages 989-995

  Stolk, Pieter ^a   Belitser, Svetlana V ^a   Leufkens, Hubert G M ^a   Heerdink, Eibert R ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Clopidogrel; Delivery of health care; Drug utilization; European Union; Pharmaceutical policy; Pharmacoepidemiology

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ADULT; ARTICLE; AUSTRIA; BELGIUM; CARDIOVASCULAR DISEASE; DENMARK; DRUG INDUSTRY; DRUG MARKETING; DRUG USE; DRUG UTILIZATION; EUROPE; FEMALE; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HUNGARY; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PORTUGAL; PRESCRIPTION; PRIORITY JOURNAL; REIMBURSEMENT; SLOVENIA; TRANSIENT ISCHEMIC ATTACK; UNITED KINGDOM;

EID: 52649091339     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2008.00331.x     Document Type: Article

References (18)

1. Tran H, Anand SS. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. JAMA 2004 292 : 1867 74.
2. Shellock D. Sanofi-Aventis benefits from patent settlement. Financial Times, 2006 March 23, p. 30.
3. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001 345 : 494 502.
4. Walley T, Folino-Gallo P, Schwabe U, et al. Variations and increase in use of statins across Europe: data from administrative databases. BMJ 2004 328 : 385 6.
5. Daly CA, Clemens F, Sendon JL, et al. The clinical characteristics and investigations planned in patients with stable angina presenting to cardiologists in Europe: from the Euro Heart Survey of Stable Angina. Eur Heart J 2005 26 : 996 1010.
6. Garrison L, Towse A. The drug budget silo mentality in Europe: an overview. Value Health 2003 6 (Suppl. S1 9.
7. Hallas J. Conducting pharmacoepidemiologic research in Denmark. Pharmacoepidemiol Drug Saf 2001 10 : 619 23.
8. Larsen J, Andersen M, Kragstrup J, et al. High persistence of statin use in a Danish population: Compliance study 1993-98. Br J Clin Pharmacol 2002 53 : 375 8.
9. World Health Organization Collaborating Centre for Drug Statistics Methodology. The ATC/DDD system. Available from: http://www.whocc.no/atcddd/ [Accessed February 20, 2006].
10. Eurostat Home Page. Available from: http://europa.eu.int/comm/eurostat/ [Accessed February 12, 2008].
11. Organisation for Economic Cooperation and Development. Health at a Glance - OECD Indicators 2005. Paris : OECD Publishing, 2005.
12. World Health Organization. The Atlas for heart disease and stroke. Available from: http://www.who.int/cardiovascular_diseases/resources/atlas/en/ [Accessed February 20, 2006].
13. Ge X. Segmental Semi-Markov Models and Applications to Sequence Analysis [Dissertation]. Irvine : University of California, 2002 2005 366 : 1673.
14. Hawkes N. Herceptin awaits licence after EU go-ahead for early cancers. The Times, 2006 April 29, p. 8.
15. Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005 26 : 804 47.
16. Smith SC, Feldman TE, Hirshfeld JW, et al. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006 47 : 216 35.
17. Radley DC, Stan SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med 2006 166 : 1021 6.
18. Van Rijkom J, Leufkens H, Crommelin D, et al. Assessment of biotechnology drugs: what are the issues? Health Policy 1999 47 : 255 74.